WILEX

Focused Cancer Therapies

Half-yearly Financial Report 2016

Press and analyst presentation

14 July 2016

Safe harbour

WILEX
Focused Cancer Therapies

Forward looking statements

This communication contains certain forward-looking statements, relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: uncertainties related to results of our clinical trials, the uncertainty of regulatory approval and commercial uncertainty, reimbursement and drug price uncertainty, the absence of sales and marketing experience and limited manufacturing capabilities, attraction and retention of technologically skilled employees, dependence on licenses, patents and proprietary technology, dependence upon collaborators, future capital needs and the uncertainty of additional funding, risks of product liability and limitations of insurance, limitations of supplies, competition from other biopharmaceutical, chemical and pharmaceutical companies, environmental, health and safety matters, availability of licensing arrangements, currency fluctuations, adverse changes in governmental rules and fiscal policies, civil unrest, acts of God, acts of war, and other factors referenced in this communication.

Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

This material is not intended as an offer or solicitation for the purchase or sale of shares of WILEX AG. This material may not be distributed within countries where it may violate applicable law.

R&D progress H1 2016

WILEX
Focused Cancer Therapies

ATAC technology	• New promising project – a therapeutic agent for multiple myeloma was produced for a tumour-specific target structure and prepared for development as a potential therapeutic agent in conjunction with a major academic research institution • Data from animal models was presented at key scientific conferences, e.g. AACR • EU patent granted for chemical building block for amatoxin • US patent granted for ATACs for tumour therapy
Clinical pipeline	• Partner Link Health submitted IND application for clinical Phase I trial in China, € 0.5 m milestone payments received
Corporate events	• AGM resolved the creation of new Authorised Capital 2016/I • Size of Supervisory Board was reduced • Appointment of Prof Dr Andreas Pahl as new Head of Research and Development

Financings had positive impact on balance sheet and cash

Financing strategy

Financing strategy announced in November 2015

- Multi-level strategy comprised of several capital measures
- Main shareholder dievini Hopp BioTech supports strategy and will invest at least € 10 m with prerequisite: subscription price of all capital increases not to exceed € 1.84 per share
- Cash reach will be extended into Q2 2017

Use of proceeds

- Ongoing development of ATAC technology
- Prepare proprietary lead candidate for clinical development & establish GMP processes
- Partnering activities

Transactions in FY 2016

Private placement with exclusion of shareholders' subscription rights in December 2015

- 930,560 new shares offered exclusively to dievini at € 1.84 per share

Rights issue using authorised capital with subscription rights in December 2015

- 443,124 new shares offered to all shareholders at € 1.84 per share

Rights issue in April 2016

- 2,248,272 new shares at € 1.84 per share

New share capital: 12,927,564

Total proceeds from all transactions: € 6.7 m

Further financing planned

Profit and loss H1 2016

WILEX
Focused Cancer Therapies

Income

€ m; rounded



Operating expenses

€ m; rounded



Net loss for the period

€ m; rounded



- **Revenue sales decreased, 2015 included revenues from the terminated Roche licence agreement**
- **Administrative costs were significantly lower than previous year, R&D expenses in line with plans**

Cost of sales
43% lower



R&D costs
47% higher



Administration
29% lower



Other expenses
50% lower



Balance sheet and cash flow

Assets

€ m; rounded



Equity and liabilities

€ m; rounded



Cash flow H1 2016

€ m; rounded



- **Total assets higher than 2015 due to capital increases**
- **Equity increased to € 13.7 m, equity ratio was 85.9%**
- **Cash balance as at 31.05.2016: € 5.1 m**
- **Average cash usage per month € 0.46 m (2015: € 0.28 m) in line with guidance**

WILEX‘s shares

Share performance H1 2016 (FY)

High: € 2.30 (11 January 2016)

Low: € 1.61 (4 January 2016)

Daily trading volume: 6,369

Analyst coverage

Equinet: target € 4.00 per share = € 51 m

Current market cap: ~€ 23.66 m

Based on 12.9 million shares

Share performance and volumes 2016



Shareholders



* Including dievini Hopp BioTech, DH-Holding Verwaltungs GmbH, Curacyte GmbH

Guidance 2016

in € m	Actual 2015	Plan
Sales revenue and other income	3.9	2.0 – 3.0
Operating expenses	(10.4)	(7.0) – (10.0)
Operating result (EBIT)	(6.5)	(4.0 – 8.0)
Total funding requirement	5.0	4.0 – 8.0
Funds required per month	0.4	0.4 – 0.6

Financial Calendar 2016

13 Oct: 9-month results

- Sales mainly driven by ATAC technology business and services at Heidelberg Pharma

Next steps and potential milestones 2016

WILEX
Focused Cancer Therapies

ATAC business	• Start cell line development of first proprietary ATAC candidate • Start of GMP transfer Amanitin (toxin and antibody) • Preclinical validation of new biomarker • Mature the technology platform for Antibody Targeted Amanitin Conjugates and potentially transfer MTAs into licence agreements

Clinical assets	• MESUPRON®
	  • Support development activities of both partners RedHill and Link Health
	  • Start clinical development in China at partner Link Health
	• REDECTANE® / RENCAREX®
	  • New partners for development and commercialisation, out-licensing

Investment Summary

WILEX
Focused Cancer Therapies

Sufficient funding, exciting target → strongly positioned for future success

- ATACs show superior efficacy against other ADCs
- ATACs can overcome resistance in tumours and treat dormant tumour cells
- Proprietary BCMA ATAC product candidate showing excellent tolerability and efficacy in vivo
- Pre-clinical development of BCMA ATAC product candidate shall start this year
- Additional pipeline candidates (PSMA-ATAC) in optimization and selection process
- Successful early stage MTA collaborations with pharma partners
- Dual strategy of product development and technology partnering offers attractive value potential



Contacts

WILEX AG
Grillparzerstr. 18
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-0
Fax: +49 (0)89-41 31 38-99
Website: www.wilex.com

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Email: katja.arnold[at]mc-services.eu
Tel.: +49 (0)89-210 288 40

Ticker data

ISIN:	DE000A11QVV0
Symbol:	WL6
Reuters:	WL6G.DE
Bloomberg:	WL6.GR